Boehringer Ingelheim Gains EU Approval for Avian Flu Vaccines

EMA Approval for Avian Flu Vaccines

The European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) has given positive opinions for two Boehringer Ingelheim vaccines targeting the H5 avian influenza virus. These vaccines are VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5, designed to enhance protection against avian flu outbreaks.

Vaccine Details

VAXXITEK® HVT+IBD+H5 is the first trivalent vaccine offering combined protection against Marek’s disease, Infectious Bursal Disease, and H5 avian influenza in a single shot for chickens and turkeys. VAXXINACT® H5 is an inactivated vaccine that protects chickens, turkeys, and ducks against the H5 virus subtype.

Impact on Outbreak Preparedness

Avian influenza, particularly the H5 strain, is a highly contagious disease affecting both domestic and wild birds, leading to significant economic losses due to culling and trade restrictions. The introduction of these vaccines aims to strengthen outbreak preparedness in the European Union, as the virus continues to evolve and spread.

DIVA Technology and Trade

Both vaccines incorporate DIVA (Differentiate Infected from Vaccinated Animals) technology, which helps distinguish between vaccinated and infected animals. This feature is crucial for monitoring disease outbreaks and reducing trade restrictions, ensuring confidence in the safety of traded animal products.

Next Steps

Following the CVMP's positive opinions, the European Commission is expected to decide on marketing authorizations under exceptional circumstances in the coming months. This decision will play a key role in integrating vaccination into bird flu control strategies across Europe.